Evaluating methods for classifying expression data.
An attractive application of expression technologies is to predict drug efficacy or safety using expression data of biomarkers. To evaluate the performance of various classification methods for building predictive models, we applied these methods on six expression datasets. These datasets were from studies using microarray technologies and had either two or more classes. From each of the original datasets, two subsets were generated to simulate two scenarios in biomarker applications. First, a 50-gene subset was used to simulate a candidate gene approach when it might not be practical to measure a large number of genes/biomarkers. Next, a 2000-gene subset was used to simulate a whole genome approach. We evaluated the relative performance of several classification methods by using leave-one-out cross-validation and bootstrap cross-validation. Although all methods perform well in both subsets for a relative easy dataset with two classes, differences in performance do exist among methods for other datasets. Overall, partial least squares discriminant analysis (PLS-DA) and support vector machines (SVM) outperform all other methods. We suggest a practical approach to take advantage of multiple methods in biomarker applications.
Man
Michael Z
MZ
Nonclinical Statistics, Pfizer Global Research and Development - Ann Arbor Laboratories, Ann Arbor, MI 48105, USA. michael.mann@pfizer.com
Dyson
Greg
G
Johnson
Kjell
K
Liao
Birong
B
D000465:Algorithms; D001185:Artificial Intelligence; D003627:Data Interpretation, Statistical; D016002:Discriminant Analysis; D015870:Gene Expression; D005819:Genetic Markers; D016018:Least-Squares Analysis; D008957:Models, Genetic; D016571:Neural Networks, Computer; D020411:Oligonucleotide Array Sequence Analysis / Q000706:statistics & numerical data; D011237:Predictive Value of Tests; D025341:Principal Component Analysis; D015203:Reproducibility of Results; D018709:Statistics, Nonparametric
D005819:Genetic Markers